Boehringer Ingelheim, WellPoint deal

Boehringer and WellPoint’s HealthCore Inc. unit have identified non-valvular atrial fibrillation (NVAF) as the first project under their July deal to collaborate on the collection of real world health economic and outcomes data. HealthCore, which is WellPoint’s outcomes research arm, and Boehringer said they chose to study NVAF because new anticoagulant therapies have begun to replace warfarin. The partners plan to study disease prevalence, treatment complications such as hospital readmissions and the use of evidence-based guidelines. ...